Legato Capital Management LLC Sells 2,627 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Legato Capital Management LLC reduced its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 22.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,005 shares of the company’s stock after selling 2,627 shares during the period. Legato Capital Management LLC’s holdings in Vaxcyte were worth $737,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. increased its position in shares of Vaxcyte by 68.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock worth $2,453,000 after acquiring an additional 8,685 shares in the last quarter. Natixis Advisors LLC increased its position in shares of Vaxcyte by 61.1% during the third quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock worth $2,594,000 after acquiring an additional 8,606 shares in the last quarter. Diversified Trust Co bought a new stake in shares of Vaxcyte during the fourth quarter worth about $1,433,000. Lisanti Capital Growth LLC increased its position in shares of Vaxcyte by 68.1% during the third quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock worth $3,715,000 after acquiring an additional 13,175 shares in the last quarter. Finally, WCM Investment Management LLC increased its position in shares of Vaxcyte by 52.6% during the third quarter. WCM Investment Management LLC now owns 140,847 shares of the company’s stock worth $15,935,000 after acquiring an additional 48,543 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

Vaxcyte Stock Performance

Vaxcyte stock opened at $83.84 on Friday. Vaxcyte, Inc. has a fifty-two week low of $58.10 and a fifty-two week high of $121.06. The stock has a market cap of $10.45 billion, a PE ratio of -18.23 and a beta of 0.98. The firm’s 50-day simple moving average is $86.67 and its 200 day simple moving average is $94.50.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 target price for the company. Needham & Company LLC reissued a “buy” rating and set a $14.00 target price on shares of Vaxcyte in a research report on Tuesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $127.71.

Insider Buying and Selling

In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $92.45, for a total value of $1,386,750.00. Following the transaction, the chief executive officer now directly owns 450,301 shares in the company, valued at $41,630,327.45. The trade was a 3.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $86.22, for a total transaction of $689,760.00. Following the completion of the transaction, the chief operating officer now owns 205,695 shares in the company, valued at approximately $17,735,022.90. The trade was a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 68,616 shares of company stock worth $6,095,681. 3.10% of the stock is owned by insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.